Braidwell’s Procept Biorobotics PRCT Stock Holding History

Braidwell’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-331,061	Closed	-$10.9M	–	85
2023 Q3	$10.9M	Buy	+331,061	New	+$11.3M	0.34%	73

Other funds holding PRCT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Braidwell's PRCT Position: Q4 2023 in Review

Braidwell sold out of Procept Biorobotics (PRCT) in Q4 2023, closing a stake of 331,061 shares — an estimated $10.9M sold.

Braidwell first reported a position in PRCT in Q3 2023 and held it in 1 quarter. The position peaked at $10.9M in Q3 2023. 145 funds tracked by Wall St. Rank hold PRCT as of Q4 2023.

Braidwell reported no remaining Procept Biorobotics position as of Q4 2023 after selling out during the quarter.
Braidwell sold 331,061 Procept Biorobotics shares in Q4 2023, an estimated $10.9M.
Braidwell first reported a position in Procept Biorobotics in Q3 2023 and held it in 1 quarter.
Braidwell's Procept Biorobotics position peaked at $10.9M in Q3 2023.
145 funds tracked by Wall St. Rank held Procept Biorobotics as of Q4 2023.

Based on Braidwell's 13F filing for Q4 2023, filed 14 Feb 2024.